Literature DB >> 154981

Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy.

D D Savage, S F Seides, B J Maron, D J Myers, S E Epstein.   

Abstract

Many patients with hypertrophic cardiomyopathy die suddenly and unexpectedly, a significant number perhaps due to arrhythmia. Of 100 patients initially evaluated for signs or symptoms suggestive of heart disease or a family history of hypertrophic cardiomyopathy, 51 were selected solely because they met the echocardiographic criteria for the disease, and 49 patients were selected primarily because they had: 1) normal sinus rhythm despite left atrial enlargement, 2) a history of syncope, 3) a family history of premature death, or 4) a history of paroxysmal atrial fibrillation. All 100 patients were studied by 24-hour ambulatory electrocardiographic monitoring and 74 of them also underwent treadmill exercise testing. More than 50% of patients in repetitive ventricular premature depolarizations, including 19% who had ventricular tachycardia. Monitoring was superior to exercise testing for exposing these arrhythmias. Two patients experienced cardiac arrest within 2 months of monitoring; in each, monitoring had revealed ventricular tachycardia. Two patients with paroxysms of supraventricular tachycardia during monitoring developed fixed atrial fibrillation within 1 year. These preliminary observations suggest that monitoring may help identify patients at increased risk for significant arrhythmic events.

Entities:  

Mesh:

Year:  1979        PMID: 154981     DOI: 10.1161/01.cir.59.5.866

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

Review 1.  Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy.

Authors:  A Selcuk Adabag; Barry J Maron
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

Review 2.  Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias.

Authors:  P J Counihan; W J McKenna
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

4.  Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm.

Authors:  F Alfonso; M P Frenneaux; W J McKenna
Journal:  Br Heart J       Date:  1989-02

Review 5.  Obstruction is unimportant in the pathophysiology of hypertrophic cardiomyopathy.

Authors:  J M Criley; R J Siegel
Journal:  Postgrad Med J       Date:  1986-06       Impact factor: 2.401

Review 6.  The frontiers of cardiomyopathy.

Authors:  J F Goodwin
Journal:  Br Heart J       Date:  1982-07

Review 7.  Ventricular arrhythmias in congestive heart failure: clinical significance and management.

Authors:  G R Khoshnevis; A Massumi
Journal:  Tex Heart Inst J       Date:  1999

8.  Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways.

Authors:  D M Krikler; M J Davies; E Rowland; J F Goodwin; R C Evans; D B Shaw
Journal:  Br Heart J       Date:  1980-03

9.  Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis.

Authors:  W J McKenna; D England; Y L Doi; J E Deanfield; C Oakley; J F Goodwin
Journal:  Br Heart J       Date:  1981-08

Review 10.  Management of arrhythmias in hypertrophic cardiomyopathy.

Authors:  J T Stewart; W J McKenna
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.